Research Article| Volume 31, ISSUE 2, P321-327, February 2009

Download started.


Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX®) in a randomized, open-label, controlled study: An a priori subgroup analysis

      This paper is only available as a PDF. To read, Please Download here.


      Objectives: This a priori subgroup analysis was conducted to assess patients' experience with a compliance device for the administration of sublingual specific immunotherapy for grass pollen-induced rhinoconjunctivitis.
      Methods: The present paper reports the results of a subgroup analysis of a multicenter, randomized, controlled, open-label European study in which adults with grass pollen-induced rhinoconjunctivitis received once-daily treatment with grass allergen tablets with or without a device to aid compliance. Treatment was given ~6 to 12 weeks before the grass pollen season, during the season (~8–10 weeks), and for up to 2 weeks after the end of the season. In the subgroup analysis, patients from Germany and the Netherlands who had been randomized to receive the compliance device were asked to complete a brief questionnaire at the final study visit. The questionnaire included 6 items concerning patients' use of the device and whether it helped them remember to take their tablets.
      Results: Of the 91 patients from Germany and the Netherlands who were randomized to use the compliance device along with grass allergen tablets, 71 returned the questionnaire. Among responders, 58 of 71 (82%) reported using the device sometimes or always, 50 of 63 (79%) found the device easy to use, 32 of 69 (46%) found that the device made it easier to remember to take tablets, and 43 of 71 (61%) indicated that they would consider using the device again.
      Conclusion: Most patients in this subgroup analysis used the compliance device as a medication reminder and rated it easy to use.

      Key words:

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bauchau V
        • Durham SR
        Prevalence and rate of diagnosis of allergic rhinitis in Europe.
        Eur Respir J. 2004; 24: 758-764
        • Simola M
        • Holopainene E
        • Malmberg H
        Changes in skin and nasal sensitivity to allergens and the course of rhinitis; a long-term follow-up study.
        Ann Allergy Asthma Immunol. 1999; 82: 152-156
        • Lombardi C
        • Passalacqua G
        • Gargioni S
        • et al.
        The natural history of respiratory allergy: A follow-up study of 99 patients up to 10 years.
        Respir Med. 2001; 95: 9-12
        • Bousquet J
        • Lockey R
        • Malling HJ
        Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper.
        J Allergy Clin Immunol. 1998; 102: 558-562
        • Des Roches A
        • Paradis L
        • Menardo JL
        • et al.
        Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.
        J Allergy Clin Immunol. 1997; 99: 450-453
        • Pajno GB
        • Barberio G
        • De Luca F
        • et al.
        Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.
        Clin Exp Allergy. 2001; 31: 1392-1397
        • Möller C
        • Dreborg S
        • Ferdousi HA
        • et al.
        Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study).
        J Allergy Clin Immunol. 2002; 109: 251-256
        • Novembre E
        • Galli E
        • Landi F
        • et al.
        Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis.
        J Allergy Clin Immunol. 2004; 114: 851-857
        • Jacobsen L
        • Niggemann B
        • Dreborg S
        • et al.
        • for the PAT Investigator Group
        Specific immunotherapy has longterm preventive effect of seasonal and perennial asthma: 10-Year follow-up on the PAT study.
        Allergy. 2007; 62: 943-948
        • Jacobsen L
        Preventive aspects of immunotherapy: Prevention for children at risk of developing asthma.
        Ann Allergy Asthma Immunol. 2001; 87: 43-46
        • Jacobsen L
        • Nüchel Petersen B
        • Wihl JA
        • et al.
        Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up.
        Allergy. 1997; 52: 914-920
        • Durham SR
        • Walker SM
        • Varga EM
        • et al.
        Long-term clinical efficacy of grass-pollen immunotherapy.
        N Engl J Med. 1999; 341: 468-475
        • Hedlin G
        • Heilborn H
        • Lilja G
        • et al.
        Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy.
        J Allergy Clin Immunol. 1995; 96: 879-885
        • Mosbech H
        • Østerballe O
        Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis.
        Allergy. 1988; 43: 523-529
        • Di Rienzo V
        • Marcucci F
        • Puccinelli P
        • et al.
        Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A 10-year prospective study.
        Clin Exp Allergy. 2003; 33: 206-210
        • Alvarez-Cuesta E
        • Bousquet J
        • Canonica GW
        • et al.
        • for the EAACI Immunotherapy Task Force
        Standards for practical allergen-specific immunotherapy.
        Allergy. 2006; 61: 1-20
        • Malling HJ
        • Lund L
        • Ipsen H
        • Poulsen L
        Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
        J Investig Allergol Clin Immunol. 2006; 16: 162-168
        • Durham SR
        • Yang WH
        • Pedersen MR
        • et al.
        Sublingual immunotherapy with once-daily grass allergen tab lets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis.
        J Allergy Clin Immunol. 2006; 117: 802-809
        • Kleine-Tebbe J
        • Ribel M
        • Herold DA
        Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: A randomized, placebocontrolled trial.
        Allergy. 2006; 61: 181-184
        • Calderón M
        • Essendrop M
        Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated.
        J Investig Allergol Clin Immunol. 2006; 16: 338-344
        • Dahl R
        • Kapp A
        • Colombo G
        • et al.
        Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.
        J Allergy Clin Immunol. 2006; 118: 434-440
        • Dahl R
        • Stender A
        • Rak S
        Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
        Allergy. 2006; 61: 185-190
        • Dahl R
        • Kapp A
        • Colombo G
        • et al.
        Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.
        J Allergy Clin Immunol. 2008; 121: 512-518
      1. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects.

      2. (Accessed)
      3. International Conference on Harmonisation Harmonised Tripartite Guideline E6 S5. Guideline for Good Clinical Practice 1996.

        • Rak S
        • Yang WH
        • Pedersen MR
        • Durham SR
        Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study.
        Qual Life Res. 2007; 16: 191-201
        • Cleemput I
        • Kesteloot K
        Economic implications of non-compliance in health care.
        Lancet. 2002; 359: 2129-2130
        • Pham-Thi N
        • de Blic J
        • Scheinmann P
        Sublingual immunotherapy in the treatment of children.
        Allergy. 2006; 61: 7-10
        • Fox AT
        • du Toit G
        Sublingual immunotherapy in children with allergic rhinitis.
        Curr Opin Allergy Clin Immunol. 2007; 20: 16-19